Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients With Chronic Systolic Heart Failure: Serial Measurement and Multimarker Testing

What Was Tested

Researchers studied Endothelin-1 in the context of chronic and systemic inflammation in this randomized controlled trial publication.

To define the role of single or serial measurement of endothelin 1 (ET-1) for prognostication beyond traditional and modern markers of risk in heart failure (HF).

Who Took Part

According to the abstract, 115 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In total, 115 patients with chronic systolic HF were followed for 10 months.

Clinical assessment and ET-1, N-terminal pro-B-type natriuretic peptide (NT-proBNP), highly sensitive troponin I (hsTnI), soluble ST2 (sST2), and galectin 3 were measured at each visit.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Endothelin-1 group and the comparison group should start out alike.

The methods mention a period of 10 months.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Chronic Disease, Echocardiography, Endothelin-1, Heart Failure, Systolic, Immunoassay and Natriuretic Peptide, Brain.

The authors tagged it with the keywords Monitoring, Multimarker panel and Prognosis.

What This Means in Plain Language

The paper is a randomized study of Endothelin-1 in 115 patients in people with chronic and systemic inflammation over 10 months.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (American journal of clinical pathology), a journal based in England.

More context: the Endothelin-1 compound page, Chronic and systemic inflammation research.